Samsung Bioepis and Teva enter into a partnership for commercialization of EPYSQLI

by
Contributor since / Followers

19 hours ago

Samsung Bioepis and Teva Pharmaceutical (NYSE:TEVA) announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the U.S..
Under the terms of the agreement, Samsung Bioepis will be responsible for

Tags: TEVA